Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy

Gynecologic Oncology

Volumn 64, Issue 1, 1997, Pages 109-113

  Mayerhofer, K ^a   Kucera, E ^a   Zeisler, H ^a   Speiser, P ^a   Reinthaller, A ^a   Sevelda, P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0031021548     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4514     Document Type: Article

References (26)

1. 1. Boring, C. C., Squires, T. S., and Tong, T. Cancer statistics, 1991, CA Cancer J. Clin. 41, 19-52 (1991).
2. 2. Menck, H. R., Garfinkel, L., and Dodd, G. D. Preliminary report of the national cancer data base, CA Cancer J. Clin. 41, 7-19 (1991).
3. 3. Omura, G., Blessing, J., and Ehrlich, C. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma, Cancer 57, 1725-1730 (1986).
4. 4. Ehrlich, C., Einhorn, L., and Williams, S. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide: A preliminary report, Cancer Treat. Rep. 63, 281-288 (1979).
5. 5. Greco, F., Julian, C., and Richardson, R. Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation, Obstet. Gynecol. 58, 199-205 (1981).
6. 6. Ozols, R. F., Rubin, S. C., Dembo, A. J., and Robboy, S. Epithelial ovarian cancer, in Principles and practice of gynecologic oncology (W. J. Hoskins, C. A. Ferez, and R. C. Young, Eds.), Lippincott, Philadelphia (1992).
7. 7. Gregory, R. E., and De Lisa, A. F. Paclitaxel: A new antineoplastic agent for refractory ovarian cancer, Clin. Pharm. 12, 401-415 (1993).
8. 8. McGuire, W. P., Rowinsky, E. K., Rosenheim, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
9. 9. Runowicz, C. D., Wiernik, P. H., Einzig, A. I., Goldberg, G. L., and Horwitz, S. B. Taxol in ovarian cancer, Cancer 71, 1591-1596 (1993).
10. 10. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol, Nature 277, 665-667 (1979).
11. 11. Kumar, N. Taxol-induced polymerization of purified tubulin: Mechanism of action, J. Biol. Chem. 256, 10435-10441, 1981.
12. 12. Hamel, E., del Campo, A., Lowe, M. C., and Lin, C. M. Interactions of Taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization, J. Biol. Chem. 256, 11887-11894 (1981).
13. 13. Schiff, P. B., and Horwitz, S. B. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins, Biochemistry 20, 3247-3252 (1981).
14. 14. Parness, J., and Horwitz, S. B. Taxol binds to polymerized tubulin in vitro, J. Cell. Biol. 91, 479-487 (1981).
15. 15. Fuchs, D. A., and Johnson, R. K. Cytologic evidence that taxol, an antineoplaxtic agent from Taxus brevifolia, acts as a mitotic spindle poison, Cancer Treat. Rep. 62, 1219-1222 (1978).
16. 16. Thipgen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., and Barrett, R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study, J. Clin. Oncol. 12, 1748-1753 (1994).
17. 17. Einzig, A., Wiernik, P., and Sasloff, J. Phase II study and long term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma, J. Clin. Oncol. 10, 1748-1753 (1992).
18. 18. Sarosy, G., Kohn, E., and Stone, D. A. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J. Clin. Oncol. 10, 1165-1170 (1992).
19. 19. Sarosy, G., Kohn, E., and Link, C. Taxol dose intensification in patients with recurrent ovarian cancer, Proc. Am. Soc. Clin. Oncol. 11, 226 (1992). [Abstract 716]
20. 20. Miller, A. B., Hoogstraten, B., and Staquet, M. Reporting results of cancer treatment, Cancer 47, 207-214 (1981).
21. 21. Einzig, A. I., Wiernik, P. H., and Sasloff, J. Phase II study of Taxol in patients with advanced ovarian cancer, Proc. Am. Assoc. Cancer Res. 31, 187 (1990). [Abstr.]
22. 22. Trimble, E. L., Arbuck, S. G., and McGuire, W. P. Options for primary chemotherapy of epithelial ovarian cancer: Taxanes, Gynecol. Oncol. 55, 114-121 (1994).
23. 23. Lipten, R. B., Apfel, S. C., Dutcher, J. P., Rosenberg, R., Kaplan, J., Berger, A., Einzig, A. I., Wiernik, P., and Schaumburg, H. H. Taxol produces a predominantly sensory neuropathy, Neurology 39, 368-373 (1989).
24. 24. Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Marzola, M., Colomba, N., and Tredici, G. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin, Cancer 75, 1141-1150 (1995).
25. 25. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., Colombo, N., Bacon, M., Santabarbara, P., Onetto, N., Winograd, B., and Canetta, R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion, J. Clin. Oncol. 12, 2654-2666 (1994).
26. 26. Sevelda, P., Mayerhofer, K., Obermair, A., Stolzlechner, J., and Kurz, C. Thrombosis with paclitaxel, Lancet 343(8899), 727 (1994) [Letter].